30 closest matches · ranked by relevance
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Recurrent Bladder Cancer · Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria — 0 participants
Advanced Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Prostate Carcinoma
Primary: Overall Survival (OS) — 14.5; 14.3 months — p=0.1707
Urinary Tract Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants
Non-Transitional Cell Carcinoma of the Urothelial Tract · Small Cell of the Bladder · Adenocarcinoma of the Bladder
Primary: Overall Response Rate — 2; 11; 2 Participants
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Urothelial Cancer
Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants
High Grade Upper Tract Urothelial Carcinoma
Primary: Complete Pathologic Response Rate — 0.103; 0.167 proportion of participants
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Proximal Urethral Cancer
Primary: Objective Response Rate — 56.4 percentage of participants
Bladder Cancer · Patient Engagement · Patient Empowerment
Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772
Bladder Cancer
Primary: Progression Free Survival — 8.2 months
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Diabetes Mellitus, Type 2
Primary: Occurrence of Urinary Tract Cancer — 0.73; 1.07; 1.34; 1.52 Events per 1000 patient years — p=0.122
Bladder Cancer · Metastatic Transitional Cell Carcinoma
Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants
Infiltrating Bladder Urothelial Carcinoma
Primary: Overall Pathological Response Rate — 57.7 % of participants
Urinary Bladder Neoplasms
Primary: Number of Grades 1-5 Adverse Events — 12; 3; 15; 9 adverse events
Bladder Cancer
Primary: Treatment Completion Rate — 67; 53 percentage of participants
Bladder Cancer
Primary: Percentage of Participants Without Recurrence (Recurrence-free Survival (RFS)) With Bacillus Calmette-Guerin (BCG) + PANVAC Compared With BCG Alone at 6 and 12 Months…